These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 33428130)
61. Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei. Dutschmann M; Menuet C; Stettner GM; Gestreau C; Borghgraef P; Devijver H; Gielis L; Hilaire G; Van Leuven F J Neurosci; 2010 Feb; 30(5):1810-21. PubMed ID: 20130190 [TBL] [Abstract][Full Text] [Related]
62. MK-8719, a Novel and Selective Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725 [TBL] [Abstract][Full Text] [Related]
63. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011 [TBL] [Abstract][Full Text] [Related]
64. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. Sydow A; Van der Jeugd A; Zheng F; Ahmed T; Balschun D; Petrova O; Drexler D; Zhou L; Rune G; Mandelkow E; D'Hooge R; Alzheimer C; Mandelkow EM J Neurosci; 2011 Feb; 31(7):2511-25. PubMed ID: 21325519 [TBL] [Abstract][Full Text] [Related]
65. Cornel Iridoid Glycoside Ameliorated Alzheimer's Disease-Like Pathologies and Necroptosis through RIPK1/MLKL Pathway in Young and Aged SAMP8 Mice. Ma D; Li Y; Zhu Y; Wei W; Zhang L; Li Y; Li L; Zhang L Evid Based Complement Alternat Med; 2021; 2021():9920962. PubMed ID: 34475966 [TBL] [Abstract][Full Text] [Related]
66. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765 [TBL] [Abstract][Full Text] [Related]
67. Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy. Ou W; Yang J; Simanauskaite J; Choi M; Castellanos DM; Chang R; Sun J; Jagadeesan N; Parfitt KD; Cribbs DH; Sumbria RK J Neuroinflammation; 2021 Dec; 18(1):312. PubMed ID: 34972522 [TBL] [Abstract][Full Text] [Related]
68. Home cage measures of Alzheimer's disease in the rTg4510 mouse model. Barabas AJ; Robbins LA; Gaskill BN Genes Brain Behav; 2022 Feb; 21(2):e12795. PubMed ID: 35044727 [TBL] [Abstract][Full Text] [Related]
70. Glucose deficit triggers tau pathology and synaptic dysfunction in a tauopathy mouse model. Lauretti E; Li JG; Di Meco A; Praticò D Transl Psychiatry; 2017 Jan; 7(1):e1020. PubMed ID: 28140402 [TBL] [Abstract][Full Text] [Related]
71. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. Berger Z; Roder H; Hanna A; Carlson A; Rangachari V; Yue M; Wszolek Z; Ashe K; Knight J; Dickson D; Andorfer C; Rosenberry TL; Lewis J; Hutton M; Janus C J Neurosci; 2007 Apr; 27(14):3650-62. PubMed ID: 17409229 [TBL] [Abstract][Full Text] [Related]
72. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy. Ward SM; Himmelstein DS; Ren Y; Fu Y; Yu XW; Roberts K; Binder LI; Sahara N Neurobiol Dis; 2014 Jul; 67():37-48. PubMed ID: 24631720 [TBL] [Abstract][Full Text] [Related]
73. Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology. Rao SS; Lago L; Volitakis I; Shukla JJ; McColl G; Finkelstein DI; Adlard PA Neurotherapeutics; 2021 Apr; 18(2):1081-1094. PubMed ID: 33410108 [TBL] [Abstract][Full Text] [Related]
74. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies. Rockenstein E; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Masliah E BMC Neurosci; 2015 Nov; 16():85. PubMed ID: 26611895 [TBL] [Abstract][Full Text] [Related]
76. Small Heat Shock Protein 22 Improves Cognition and Learning in the Tauopathic Brain. Rodriguez Ospina S; Blazier DM; Criado-Marrero M; Gould LA; Gebru NT; Beaulieu-Abdelahad D; Wang X; Remily-Wood E; Chaput D; Stevens S; Uversky VN; Bickford PC; Dickey CA; Blair LJ Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055033 [TBL] [Abstract][Full Text] [Related]
77. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. Ozcelik S; Fraser G; Castets P; Schaeffer V; Skachokova Z; Breu K; Clavaguera F; Sinnreich M; Kappos L; Goedert M; Tolnay M; Winkler DT PLoS One; 2013; 8(5):e62459. PubMed ID: 23667480 [TBL] [Abstract][Full Text] [Related]
78. The Reduction of Tau Hyperphosphorylation by Cornel Iridoid Glycosides Is Mediated by Their Influence on Calpain Activity. Guo K; Yang C; Zhang L Evid Based Complement Alternat Med; 2022; 2022():9213046. PubMed ID: 35096120 [TBL] [Abstract][Full Text] [Related]
79. Zinc Exacerbates Tau Pathology in a Tau Mouse Model. Craven KM; Kochen WR; Hernandez CM; Flinn JM J Alzheimers Dis; 2018; 64(2):617-630. PubMed ID: 29914030 [TBL] [Abstract][Full Text] [Related]
80. Impaired Src signaling and post-synaptic actin polymerization in Alzheimer's disease mice hippocampus--linking NMDA receptors and the reelin pathway. Mota SI; Ferreira IL; Valero J; Ferreiro E; Carvalho AL; Oliveira CR; Rego AC Exp Neurol; 2014 Nov; 261():698-709. PubMed ID: 25128699 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]